• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Disproportionate Rates of Liver Injury in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor in Queensland, Australia.

作者信息

Johnson Ellie, Riddles Timothy, Smith Daniel, Henderson Daniel, Masel Philip, Reid David W, Moore Vanessa, Evans Ieuan E S

机构信息

Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.

Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.

出版信息

Gastro Hep Adv. 2025 Feb 8;4(6):100641. doi: 10.1016/j.gastha.2025.100641. eCollection 2025.

DOI:10.1016/j.gastha.2025.100641
PMID:40692822
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12277765/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9b/12277765/e158fdaf3a02/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9b/12277765/fa4cc84ac392/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9b/12277765/e158fdaf3a02/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9b/12277765/fa4cc84ac392/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad9b/12277765/e158fdaf3a02/gr2.jpg

相似文献

1
Disproportionate Rates of Liver Injury in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor in Queensland, Australia.澳大利亚昆士兰州接受依列卡福妥/替扎卡福妥/依伐卡托治疗的囊性纤维化患者中肝损伤发生率不均衡
Gastro Hep Adv. 2025 Feb 8;4(6):100641. doi: 10.1016/j.gastha.2025.100641. eCollection 2025.
2
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.12岁及以上囊性纤维化患者使用万扎卡托-替扎卡托-地替瓦卡托与依列卡托-替扎卡托-艾伐卡托的对比研究（SKYLINE试验VX20 - 121 - 102和VX20 - 121 - 103）：两项随机、活性对照3期试验的结果
Lancet Respir Med. 2025 Mar;13(3):256-271. doi: 10.1016/S2213-2600(24)00411-9. Epub 2025 Jan 2.
3
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对携带 II 类 CFTR 基因突变（最常见的是 F508del）的囊性纤维化患者的校正治疗（有或没有增效剂）。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4.
4
Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment.一项评估 Elexacaftor/Tezacaftor/Ivacaftor 在无囊性纤维化且具有中度肝损伤的受试者中的安全性和药代动力学的 I 期研究。
Eur J Drug Metab Pharmacokinet. 2022 Nov;47(6):817-825. doi: 10.1007/s13318-022-00791-8. Epub 2022 Aug 29.
5
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.依列卡福妥联合替扎卡福妥和依伐卡托对比替扎卡福妥联合依伐卡托治疗F508del-CFTR纯合子囊性纤维化患者的疗效和安全性：一项为期24周的多中心、随机、双盲、活性对照3b期试验
Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9. Epub 2021 Dec 20.
6
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.无 F508del CFTR 变异的囊性纤维化患者使用依伐卡托、泰它西普和埃拉卡托的法国扩大同情用药计划：一项真实世界研究。
Lancet Respir Med. 2024 Nov;12(11):888-900. doi: 10.1016/S2213-2600(24)00208-X. Epub 2024 Aug 13.
7
Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.依伐卡托-替扎卡托-艾列卡托、替扎卡托-依伐卡托和鲁玛卡托-依伐卡托治疗囊性纤维化：系统评价与经济学评估
Health Technol Assess. 2025 May;29(19):1-111. doi: 10.3310/CPLD8546.
8
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
9
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对具有 II 类 CFTR 基因突变（最常见的是 F508del）的囊性纤维化患者的校正治疗（含或不含增效剂）。
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3.
10
Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia.在澳大利亚，接受依列卡福妥/替扎卡福妥/依伐卡托治疗的囊性纤维化患者中维持治疗的使用减少。
Clin Ther. 2025 Sep;47(9):813-815. doi: 10.1016/j.clinthera.2025.05.016. Epub 2025 Jun 21.

本文引用的文献

1
Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor: A pharmacovigilance analysis of the FDA adverse event reporting system (FAERS).依来曲泊帕治疗免疫性血小板减少症的有效性和安全性：一项随机、双盲、安慰剂对照的 III 期临床试验
J Cyst Fibros. 2024 May;23(3):566-572. doi: 10.1016/j.jcf.2024.01.001. Epub 2024 Jan 16.
2
Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre.在一家大型成人单一囊性纤维化中心，依列卡福妥/替扎卡福妥/依伐卡福妥对肝脏检查的纵向影响。
J Cyst Fibros. 2023 Mar;22(2):256-262. doi: 10.1016/j.jcf.2023.01.007. Epub 2023 Jan 19.
3
Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor.
依列卡福妥/依伐卡托/替扎卡福妥所致药物性肝损伤
J Cyst Fibros. 2022 Mar;21(2):e99-e101. doi: 10.1016/j.jcf.2021.07.001. Epub 2021 Jul 16.
4
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.依伐卡托与泰比卡托和艾克卡托三联复方药物治疗携带单个 F508del 突变的囊性纤维化
N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31.